Clinical Trial: Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

U.S., Dec. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07264517) titled 'Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).' on Nov. 24.

Brief Summary: This is a Phase 2, multi-site, double-masked, randomized, vehicle-controlled, study designed to evaluate the safety, tolerability, and efficacy in adult participants with DED.

Study Start Date: Nov. 03

Study Type: INTERVENTIONAL

Condition: Dry Eye Disease

Intervention: DRUG: GRF312 5%

Immune Globulin (Human), (GRF312 5% Ophthalmic Solution

OTHER: Placebo Comparator

Vehicle.

Recruitment Status: RECRUITING

Sponsor: Instituto Grifols, S.A.

Disclaimer: Curated by HT Syndication....